<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 /home/lopez/grobid/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Usefulness of PET/CT in the diagnosis of recurrent or metastasized differentiated thyroid carcinoma</title>
			</titleStmt>
			<publicationStmt>
				<publisher>Spandidos Publications</publisher>
				<availability status="unknown"><p>Copyright Spandidos Publications</p>
				</availability>
				<date type="published" when="2016-02-15">2016-02-15</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Cun-Zhi</forename><surname>Lu</surname></persName>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><roleName>Dr</roleName><forename type="first">Su-Sheng</forename><surname>Cao</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Thyroid Surgery</orgName>
								<orgName type="institution">Xuzhou Central Hospital</orgName>
								<address>
									<postCode>221009</postCode>
									<settlement>Xuzhou</settlement>
									<region>Jiangsu</region>
									<country key="CN">P.R. China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Wei</forename><surname>Wang</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Thyroid Surgery</orgName>
								<orgName type="institution">Xuzhou Central Hospital</orgName>
								<address>
									<postCode>221009</postCode>
									<settlement>Xuzhou</settlement>
									<region>Jiangsu</region>
									<country key="CN">P.R. China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jun</forename><surname>Liu</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Thyroid Surgery</orgName>
								<orgName type="institution">Xuzhou Central Hospital</orgName>
								<address>
									<postCode>221009</postCode>
									<settlement>Xuzhou</settlement>
									<region>Jiangsu</region>
									<country key="CN">P.R. China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ning</forename><surname>Fu</surname></persName>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Feng</forename><surname>Lu</surname></persName>
						</author>
						<author>
							<affiliation key="aff1">
								<orgName type="department">Department of Thyroid Surgery, Xuzhou Central Hospital</orgName>
								<address>
									<addrLine>199 Liberation of South Road</addrLine>
									<postCode>221009</postCode>
									<settlement>Xuzhou</settlement>
									<region>Jiangsu</region>
									<country key="CN">P.R. China</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Usefulness of PET/CT in the diagnosis of recurrent or metastasized differentiated thyroid carcinoma</title>
					</analytic>
					<monogr>
						<title level="j" type="main">Oncology Letters</title>
						<idno type="ISSN">1792-1074</idno>
						<idno type="eISSN">1792-1082</idno>
						<imprint>
							<publisher>Spandidos Publications</publisher>
							<biblScope unit="volume">11</biblScope>
							<biblScope unit="issue">4</biblScope>
							<biblScope unit="page" from="2420" to="2423"/>
							<date type="published" when="2016-02-15" />
						</imprint>
					</monogr>
					<idno type="DOI">10.3892/ol.2016.4229</idno>
					<idno type="PMID">27073490</idno>
					<idno type="PMCID">PMC4812582</idno>
					<ptr type="open-access" target="http://www.spandidos-publications.com/10.3892/ol.2016.4229/download" />
					<note type="submission">Received October 7, 2015; Accepted February 15, 2016</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.6.2-SNAPSHOT" ident="GROBID" when="2020-08-13T22:42+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>18 F-fluorodeoxyglucose positron emission tomography/ computed tomography</term>
					<term>differentiated thyroid carcinoma</term>
					<term>tumour recurrence</term>
					<term>metastasization</term>
				</keywords>
			</textClass>
			<abstract>
				<p>The aim of the present study was to determine the usefulness of the positron emission tomography/computed tomography (PET/CT) with 18 F-fluorodeoxyglucose (FDG) in the detection of recurrence or metastasization of differentiated thyroid carcinoma (DTC) in patients with abnormal thyroglobulin levels and negative findings on the 131 I-diagnostic whole-body scanning (dWBS). Fifteen patients with DTC, abnormal thyroglobulin levels, and negative 131 I-dWBS findings were scanned using the 18 F-FDG PET/CT. Positive diagnosis was based on postoperative histologic findings, and clinical and imaging follow-up results obtained in the subsequent 6 months. In addition, preoperative and postoperative thyroglobulin levels were compared. Using the findings of 18 F-FDG PET/CT and data on confirmed positive diagnosis, sensitivity and positive predictive value (PPV) were calculated. Sensitivity and PPV of PET/CT in detecting recurrence or metastasisization of DTC were 93.30 and 91.40%, respectively. Furthermore, postoperative thyroglobulin levels were markedly lower compared to the preoperative levels (respectively, 4.67±1.71 vs. 58.53±18.34 ng/ml; p&lt;0.05). PET/CT scan with 18 F-FDG is an informative technique for the detection of recurrent or metastasized DTC in patients with abnormal thyroglobulin levels and negative 131 I-dWBS findings. 18 F-FDG PET/CT imaging. The Philips GXL 16 PET/CT scanning instrument (Philips Medical Systems, Inc., Cleveland, OH, USA) was used. The patients fasted for ≥6 h prior to scanning. Strict blood glucose levels (non-diabetic patients, &lt;6.1 mmol/l; patients with diabetes, &lt;8.3 mmol/l) were maintained. The patients were intravenously administered 270-370 MBq of</p>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Introduction</head><p>The incidence of thyroid carcinoma is the highest among head and neck carcinomas. Differentiated thyroid carcinoma (DTC) accounts for 90% of thyroid cancers, with 20% of patients experiencing disease relapse, which decreases survival rates <ref type="bibr" target="#b0">(1)</ref>. A timely diagnosis of thyroid cancer recurrence is critical. Evaluation of serum thyroglobulin and 131 I-diagnostic whole-body scanning (dWBS) are the most commonly employed detection techniques. However, 15-20% of patients with abnormal thyroglobulin levels show negative findings on 131 I-dWBS <ref type="bibr" target="#b1">(2,</ref><ref type="bibr" target="#b2">3)</ref>. Furthermore, it is difficult to differentiate the recurrence of DTC from cicatricial tissue by computed tomography (CT), positron emission tomography (PET), magnetic resonance imaging (MRI), or ultrasound <ref type="bibr" target="#b4">(4)</ref>. Subsequently, PET/CT has been introduced in the diagnostics of DTC, since PET/CT shows metabolic activity and anatomical abnormalities, characteristic of the tumour.</p><p>Between December 2005 and June 2013, <ref type="bibr" target="#b18">18</ref> F-fluorodeoxyglucose (FDG) PET/CT was utilized to diagnose 15 patients with DTC. The results identified 18 F-FDG PET/CT as a valuable detecting technique for the recurrence or metastasization of DTC.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Materials and methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Patients.</head><p>Fifteen patients with DTC were admitted to the Department of Nuclear Medicine of the Xuzhou Central Hospital (Xuzhou, China) between December 2005 and June 2013. There were 3 male and 12 female patients, aged 25-58 years, with a median age of 46 years <ref type="table" target="#tab_0">(Table I)</ref>. The patients were diagnosed with DTC, and underwent total or subtotal thyroidectomy.</p><p>The pathological types comprised 14 cases of papillary carcinoma and 1 case of follicular carcinoma. The patients received 1 or several courses of postoperative treatment with 131 I: 1 patient was treated once, 4 patients were treated twice, 6 patients were treated three times, 2 patients were treated four times, 1 patient was treated six times, and the remaining patient was treated eight times. At the follow up after the treatment, elevated levels of thyroglobulin (&gt;20 ng/ml) and negative 131 I-dWBS findings were present in each of these patients. Subsequently, tumour recurrence or metastasization was suspected. The patients underwent PET/CT examination. Patients continued receiving thyroidin pills following surgery, including during PET/CT, to avoid deterioration of the tumour.  18 F-FDG (4.4 MBq/kg). After 60 min and prior to the scanning, the patients were required to empty their bladders.</p><p>Collection ranges were from the basilar part to the proximal femur. The 16-slice helical CT scanning parameters were 140 kV, 320 mA, with flat sweeping. Data were analyzed by image fusion following iterative reconstruction, obtaining coronal, sagittal and cross-sectional CT, PET and PET/CT fusion images. The PET/CT images were reviewed independently by two radiologists who calculated a standardized uptake value of radioactive hot lesion. A standardized uptake value of ≥2.5 localized in metastatic regions was considered as indicative of tumour metastasization.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Diagnostic criteria of tumour recurrence or metastasization.</head><p>Based on the positive results of PET/CT scanning, the lesions located in the neck underwent surgical excision, and postoperative histopathology was carried out. The patients were monitored for their serum thyroglobulin levels for 1 month. If the lesions were located in the organs where surgical excision was problematic, the status was determined by clinical situation and the follow-up imaging results within 6 months after the initial PET/CT examination.</p><p>Data analysis. The PET/CT images were qualitatively ranked as true positive, false negative, and false positive. Sensitivity and positive predictive value (PPV) for the diagnosis of recurrence and metastasization of DTC were calculated.</p><p>Statistical analysis. The SPSS 13.0 statistical software (SPSS, Inc., Chicago, IL, USA) was used for statistical analysis. Data were presented as mean ± standard deviation. The differences were tested using the paired t-test. P&lt;0.05 was considered to indicate a statistically significant difference.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head><p>In 14 patients, PET/CT scanning had a sensitivity of 93.33%. The 14 patients were found to have 40 tumour recurrences or metastases, of which 35 were cervical lymph node metastases <ref type="figure" target="#fig_0">(Fig. 1)</ref>. The tumours were excised and were identified by postoperative pathology as being tumour metastases in 32 cases and as inflammatory changes in 3 cases. Thus, PPV comprised 91.43%. In 1 patient, 5 lumps were located in the lungs and the mediastinum. No biopsy or surgical intervention were conducted in this patient. The lumps increased during the follow up for 6 months, confirming their metastatic nature.</p><p>One patient had negative PET/CT findings and developed neck lumps after 6 months of follow up, which were confirmed as tumour metastases.</p><p>A total of 13 patients with preoperative serum thyroglobulin levels of 58.53±18.34 ng/ml underwent surgery. Their postoperation serum thyroglobulin levels were 4.67±1.71 ng/ml (p&lt;0.05 vs. preoperative).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p>Examination of thyroglobulin levels and 131 I-dWBS following treatment is important for tumour monitoring and the detection of metastasization in DTC (5). Elevated thyroglobulin levels indicate recurrence or metastasization, resulting in 131 I-dWBS scans being able to locate the tumour. When 131 I-dWBS shows negative findings, B-mode ultrasound, CT, MRI, PET or other imaging techniques are used to localize recurrent or metastatic tumour. The first three methods are mainly used to locate the tumour by anatomical abnormalities, while PET reveals the tumour through metabolic abnormalities <ref type="bibr" target="#b6">(6)</ref>. Each of these techniques has its advantages and limitations. By contrast, PET/CT imaging can simultaneously reveal metabolic status and anatomical location of the lesion, thus combining the advantages of PET and CT <ref type="bibr" target="#b7">(7)</ref>. This technique is useful in difficult diagnoses, such as that for postoperative scars or nodules, which lack typical benign or malignant signs. Malignant tumours consume glucose at 10-fold higher rates than normal or scar tissue, and this feature enables precise differential diagnosis in those cases <ref type="bibr" target="#b8">(8)</ref>. Therefore, combined functional and morphological examination during PET/CT can improve the ability to detect recurrent and metastatic tumours <ref type="bibr" target="#b9">(9)</ref>.</p><p>The diagnostic efficiency of 18 F-FDG PET/CT imaging in the postoperative follow up of patients with DTC depends on patient selection, sample size, thyroglobulin levels, and thyroid-stimulating hormone levels <ref type="bibr" target="#b10">(10)</ref>. Sensitivity and PPV for recurrence and metastasization of DTC range from 66 to 93.3% and from 87.5 to 100%, respectively <ref type="bibr" target="#b11">(11)</ref><ref type="bibr" target="#b12">(12)</ref><ref type="bibr" target="#b13">(13)</ref>. These values are significantly higher than those achieved by B-mode ultrasound, CT, MRI, or PET alone. In the present study, sensitivity and PPV were 93.33 and 91.43%, respectively, for patients with positive thyroglobulin levels and negative 131 I-dWBS findings. This is in agreeement with previous findings <ref type="bibr" target="#b14">(14)</ref><ref type="bibr" target="#b15">(15)</ref><ref type="bibr" target="#b16">(16)</ref><ref type="bibr" target="#b17">(17)</ref><ref type="bibr" target="#b18">(18)</ref><ref type="bibr" target="#b19">(19)</ref>. In such patients, metastatic tumour is more aggressive, which leads to elevation of the sensitivity of <ref type="bibr" target="#b18">18</ref> F-FDG PET/CT imaging. However, tumours that uptake iodine do not uptake FDG, therefore, <ref type="bibr" target="#b18">18</ref> F-FDG PET/CT cannot fully replace 131 I-dWBS and should not be recommended for routine screening for recurrent or metastatic DTC.</p><p>In conclusion, findings of the present study indicate that 18 F-FDG PET/CT imaging is an informative technique for the detection of recurrence or metastasization of DTC in patients with positive thyroglobulin levels and negative 131 I-dWBS.</p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Figure 1 .</head><label>1</label><figDesc>Cervical lymph node metastasis revealed by positron emission tomography/computed tomography (PET/CT) scanning. (A) CT imaging shows no significant neck mass. (B) PET imaging shows two lumpy abnormal radioactive concentration shadows on the right side of the neck. (C) PET/CT imaging shows two abnormal fluorodeoxyglucose hypermetabolism areas in the sternocleidomastoid region of the right side of the neck, which were considered lymph node metastases.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table I .</head><label>I</label><figDesc>Demographic and clinical data of 15 study patients.</figDesc><table><row><cell>Patient,</cell><cell></cell><cell cols="2">Age, Histological type</cell><cell>PET/CT</cell><cell>Surgery/follow-up</cell><cell>Preoperative</cell><cell>Postoperative</cell></row><row><cell>no.</cell><cell cols="3">Gender years of the tumour</cell><cell>diagnosis</cell><cell>confirmation</cell><cell cols="2">thyroglobulin, ng/ml thyroglobulin, ng/m</cell></row><row><cell>1</cell><cell cols="2">Female 36</cell><cell>Papillary</cell><cell>2 cervical</cell><cell>2 in neck</cell><cell>53.36</cell><cell>4.34</cell></row><row><cell></cell><cell></cell><cell></cell><cell>carcinoma</cell><cell>lymph nodes</cell><cell></cell><cell></cell><cell></cell></row><row><cell>2</cell><cell cols="2">Female 45</cell><cell>Papillary</cell><cell>2 cervical</cell><cell>2 in neck</cell><cell>34.51</cell><cell>2.47</cell></row><row><cell></cell><cell></cell><cell></cell><cell>carcinoma</cell><cell>lymph nodes</cell><cell></cell><cell></cell><cell></cell></row><row><cell>3</cell><cell>Male</cell><cell>33</cell><cell>Papillary</cell><cell>2 cervical</cell><cell>2 in neck</cell><cell>61.74</cell><cell>5.02</cell></row><row><cell></cell><cell></cell><cell></cell><cell>carcinoma</cell><cell>lymph nodes</cell><cell></cell><cell></cell><cell></cell></row><row><cell>4</cell><cell cols="2">Female 48</cell><cell>Follicular</cell><cell>4 cervical</cell><cell>4 in neck</cell><cell>66.85</cell><cell>5.77</cell></row><row><cell></cell><cell></cell><cell></cell><cell>carcinoma</cell><cell>lymph nodes</cell><cell></cell><cell></cell><cell></cell></row><row><cell>5</cell><cell cols="2">Female 25</cell><cell>Papillary</cell><cell>3 cervical</cell><cell>2 in neck</cell><cell>56.27</cell><cell>4.73</cell></row><row><cell></cell><cell></cell><cell></cell><cell>carcinoma</cell><cell>lymph nodes</cell><cell></cell><cell></cell><cell></cell></row><row><cell>6</cell><cell cols="2">Female 58</cell><cell>Papillary</cell><cell>4 cervical</cell><cell>3 in neck</cell><cell>72.02</cell><cell>6.08</cell></row><row><cell></cell><cell></cell><cell></cell><cell>carcinoma</cell><cell>lymph nodes</cell><cell></cell><cell></cell><cell></cell></row><row><cell>7</cell><cell>Male</cell><cell>55</cell><cell>Papillary</cell><cell>2 cervical</cell><cell>2 in neck</cell><cell>42.25</cell><cell>3.34</cell></row><row><cell></cell><cell></cell><cell></cell><cell>carcinoma</cell><cell>lymph nodes</cell><cell></cell><cell></cell><cell></cell></row><row><cell>8</cell><cell cols="2">Female 29</cell><cell>Papillary</cell><cell>2 cervical</cell><cell>2 in neck</cell><cell>58.13</cell><cell>4.86</cell></row><row><cell></cell><cell></cell><cell></cell><cell>carcinoma</cell><cell>lymph nodes</cell><cell></cell><cell></cell><cell></cell></row><row><cell>9</cell><cell cols="2">Female 52</cell><cell>Papillary</cell><cell>2 cervical</cell><cell>2 in neck</cell><cell>49.61</cell><cell>3.53</cell></row><row><cell></cell><cell></cell><cell></cell><cell>carcinoma</cell><cell>lymph nodes</cell><cell></cell><cell></cell><cell></cell></row><row><cell>10</cell><cell cols="2">Female 40</cell><cell>Papillary</cell><cell>1 cervical</cell><cell>1 in neck</cell><cell>26.68</cell><cell>1.18</cell></row><row><cell></cell><cell></cell><cell></cell><cell>carcinoma</cell><cell>lymph node</cell><cell></cell><cell></cell><cell></cell></row><row><cell>11</cell><cell cols="2">Female 50</cell><cell>Papillary</cell><cell>5 cervical</cell><cell>4 in neck</cell><cell>83.43</cell><cell>6.71</cell></row><row><cell></cell><cell></cell><cell></cell><cell>carcinoma</cell><cell>lymph nodes</cell><cell></cell><cell></cell><cell></cell></row><row><cell>12</cell><cell cols="2">Female 42</cell><cell>Papillary</cell><cell>3 cervical</cell><cell>3 in neck</cell><cell>92.62</cell><cell>7.29</cell></row><row><cell></cell><cell></cell><cell></cell><cell>carcinoma</cell><cell>lymph nodes</cell><cell></cell><cell></cell><cell></cell></row><row><cell>13</cell><cell cols="2">Female 52</cell><cell>Papillary</cell><cell>3 cervical</cell><cell>3 in neck</cell><cell>63.45</cell><cell>5.43</cell></row><row><cell></cell><cell></cell><cell></cell><cell>carcinoma</cell><cell>lymph nodes</cell><cell></cell><cell></cell><cell></cell></row><row><cell>14</cell><cell cols="2">Female 49</cell><cell>Papillary</cell><cell>3 in the lung and</cell><cell>3 in lung and</cell><cell>475.03</cell><cell>-</cell></row><row><cell></cell><cell></cell><cell></cell><cell>carcinoma</cell><cell cols="2">2 in the mediastinum 2 in mediastinum</cell><cell></cell><cell></cell></row><row><cell>15</cell><cell>Male</cell><cell>46</cell><cell>Papillary</cell><cell>Negative</cell><cell>1 in neck</cell><cell>46.02</cell><cell>-</cell></row><row><cell></cell><cell></cell><cell></cell><cell>carcinoma</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="5">PET, positron emission tomography; CT, computed tomography.</cell><cell></cell><cell></cell><cell></cell></row></table><note></note></figure>
		</body>
		<back>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">New insights in the treatment of radioiodine refractory differentiated thyroid carcinomas</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Emilie</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Tezo</forename><surname>Karedan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Cesar</forename><forename type="middle">A</forename><surname>Perez</surname></persName>
		</author>
		<idno type="DOI">10.1097/cad.0000000000000247</idno>
		<idno type="PMID">25974026</idno>
	</analytic>
	<monogr>
		<title level="j">Anti-Cancer Drugs</title>
		<title level="j" type="abbrev">Anti-Cancer Drugs</title>
		<idno type="ISSN">0959-4973</idno>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="689" to="697" />
			<date type="published" when="2015-08" />
			<publisher>Ovid Technologies (Wolters Kluwer Health)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Clinical application and progress of PET/CT in differentiated thyroid carcinoma with positive TG and negative 131 I scanning</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Z</forename><surname>Gao</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Chin Med Device Inf</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="8" to="12" />
			<date type="published" when="2011" />
		</imprint>
	</monogr>
	<note>In Chinese</note>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">F-18 FDG-PET/CT Evaluation of Patients With Differentiated Thyroid Cancer With Negative I-131 Total Body Scan and High Thyroglobulin Level</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Francesco</forename><surname>Bertagna</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Giovanni</forename><surname>Bosio</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Giorgio</forename><surname>Biasiotto</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Carlo</forename><surname>Rodella</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Erinda</forename><surname>Puta</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Sara</forename><surname>Gabanelli</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Silvia</forename><surname>Lucchini</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Giuseppe</forename><surname>Merli</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Giordano</forename><surname>Savelli</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Raffaele</forename><surname>Giubbini</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Joshua</forename><surname>Rosenbaum</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Abass</forename><surname>Alavi</surname></persName>
		</author>
		<idno type="DOI">10.1097/rlu.0b013e3181b7d95c</idno>
		<idno type="PMID">19851169</idno>
	</analytic>
	<monogr>
		<title level="j">Clinical Nuclear Medicine</title>
		<title level="j" type="abbrev">Clinical Nuclear Medicine</title>
		<idno type="ISSN">0363-9762</idno>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="756" to="761" />
			<date type="published" when="2009-11" />
			<publisher>Ovid Technologies (Wolters Kluwer Health)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">/CT evaluation of patients with differentiated thyroid cancer with negative I-131 total body scan and high thyroglobulin level</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><surname>Fdg-Pet</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Nucl Med</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="page" from="756" to="761" />
			<date type="published" when="2009" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Value of fluorodeoxyglucose pet/computed tomography patient management and outcomes in thyroid cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Laurens</forename><surname>St</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Wjg</forename><surname>Oyen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pet Clinics</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page" from="265" to="278" />
			<date type="published" when="2015" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Novel therapies for thyroid cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jolanta</forename><surname>Krajewska</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Barbara</forename><surname>Jarzab</surname></persName>
		</author>
		<idno type="DOI">10.1517/14656566.2014.969240</idno>
		<idno type="PMID">25318585</idno>
	</analytic>
	<monogr>
		<title level="j">Expert Opinion on Pharmacotherapy</title>
		<title level="j" type="abbrev">Expert Opinion on Pharmacotherapy</title>
		<idno type="ISSN">1465-6566</idno>
		<idno type="ISSNe">1744-7666</idno>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="issue">18</biblScope>
			<biblScope unit="page" from="2641" to="2652" />
			<date type="published" when="2014-10-16" />
			<publisher>Informa Healthcare</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Current Status and Future Perspectives in Differentiated Thyroid Cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Tae</forename><forename type="middle">Yong</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Won</forename><forename type="middle">Gu</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Won</forename><forename type="middle">Bae</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Young</forename><forename type="middle">Kee</forename><surname>Shong</surname></persName>
		</author>
		<idno type="DOI">10.3803/enm.2014.29.3.217</idno>
		<idno type="PMID">25309778</idno>
		<idno type="PMCID">PMC4192824</idno>
		<ptr type="open-access" target="http://synapse.koreamed.org/Synapse/Data/PDFData/2008ENM/enm-29-217.pdf" />
	</analytic>
	<monogr>
		<title level="j">Endocrinology and Metabolism</title>
		<title level="j" type="abbrev">Endocrinol Metab</title>
		<idno type="ISSN">2093-596X</idno>
		<idno type="ISSNe">2093-5978</idno>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page">217</biblScope>
			<date type="published" when="2014" />
			<publisher>Korean Endocrine Society (KAMJE)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Current status of PET imaging of differentiated thyroid cancer with second generation radiopharmaceuticals</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C1</forename><surname>Lauri</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Di</forename><surname>Traglia</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Galli</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><surname>Pizzichini</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Signore</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Q J Nucl Med Mol Imaging</title>
		<imprint>
			<biblScope unit="volume">59</biblScope>
			<biblScope unit="page" from="105" to="115" />
			<date type="published" when="2015" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Differenzierte Schilddrüsenkarzinome</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">V1</forename><surname>Tiedje</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><forename type="middle">W</forename><surname>Schmid</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><surname>Weber</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Bockisch</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Führer</surname></persName>
		</author>
		<idno type="DOI">10.1007/s00108-014-3637-0</idno>
		<idno type="PMID">25627410</idno>
	</analytic>
	<monogr>
		<title level="j">Der Internist</title>
		<title level="j" type="abbrev">Internist</title>
		<idno type="ISSN">0020-9554</idno>
		<idno type="ISSNe">1432-1289</idno>
		<imprint>
			<biblScope unit="volume">56</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="153" to="168" />
			<date type="published" when="2015-01-29" />
			<publisher>Springer Nature</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Clinical implication of F-18 FDG PET/CT for differentiated thyroid cancer in patients with negative diagnostic iodine-123 scan and elevated thyroglobulin</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S-J</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><forename type="middle">H</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">I-J</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y-K</forename><surname>Kim</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.clinimag.2009.06.017</idno>
	</analytic>
	<monogr>
		<title level="j">Clinical Imaging</title>
		<title level="j" type="abbrev">Clinical Imaging</title>
		<idno type="ISSN">0899-7071</idno>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="414" to="415" />
			<date type="published" when="2009-09" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">The role of TSH for 18F-FDG-PET in the diagnosis of recurrence and metastases of differentiated thyroid carcinoma with elevated thyroglobulin and negative scan: a meta-analysis</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Chao</forename><surname>Ma</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jiawei</forename><surname>Xie</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yanhui</forename><surname>Lou</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yanyan</forename><surname>Gao</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Shuyao</forename><surname>Zuo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Xufu</forename><surname>Wang</surname></persName>
		</author>
		<idno type="DOI">10.1530/eje-10-0256</idno>
		<idno type="PMID">20484385</idno>
		<ptr type="open-access" target="https://eje.bioscientifica.com/downloadpdf/journals/eje/163/2/177.pdf" />
	</analytic>
	<monogr>
		<title level="j">European Journal of Endocrinology</title>
		<idno type="ISSN">0804-4643</idno>
		<idno type="ISSNe">1479-683X</idno>
		<imprint>
			<biblScope unit="volume">163</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="177" to="183" />
			<date type="published" when="2010-08" />
			<publisher>Bioscientifica</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Detection of Residual Lymph Node Metastases in High-Risk Papillary Thyroid Cancer Patients Receiving Adjuvant I-131 Therapy</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Koichiro</forename><surname>Kaneko</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Koichiro</forename><surname>Abe</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Shingo</forename><surname>Baba</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Takuro</forename><surname>Isoda</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Hidetake</forename><surname>Yabuuchi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Masayuki</forename><surname>Sasaki</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Masamitsu</forename><surname>Hatakenaka</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Hiroshi</forename><surname>Honda</surname></persName>
		</author>
		<idno type="DOI">10.1097/rlu.0b013e3181c3b737</idno>
		<idno type="PMID">20026964</idno>
	</analytic>
	<monogr>
		<title level="j">Clinical Nuclear Medicine</title>
		<title level="j" type="abbrev">Clinical Nuclear Medicine</title>
		<idno type="ISSN">0363-9762</idno>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="6" to="11" />
			<date type="published" when="2010-01" />
			<publisher>Ovid Technologies (Wolters Kluwer Health)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Recombinant thyrotropin stimulation improves 18F-FDG PET/CT sensitivity in patients with recurrent differentiated thyroid cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Panareo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Rossi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Cittanti</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Giganti</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><surname>Prandini</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Franceschetti</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">De</forename><surname>Biasi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">V</forename></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Lunardon</forename></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Feggi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Nucl Med</title>
		<imprint>
			<biblScope unit="volume">52</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page">1308</biblScope>
			<date type="published" when="2011" />
		</imprint>
	</monogr>
	<note>Suppl</note>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Assessment of the Incremental Value of Recombinant Thyrotropin Stimulation before 2-[18F]-Fluoro-2-Deoxy-d-Glucose Positron Emission Tomography/Computed Tomography Imaging to Localize Residual Differentiated Thyroid Cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Leboulleux</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><forename type="middle">R</forename><surname>Schroeder</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><forename type="middle">L</forename><surname>Busaidy</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Auperin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Corone</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><forename type="middle">A</forename><surname>Jacene</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">E</forename><surname>Ewertz</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Bournaud</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">L</forename><surname>Wahl</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">I</forename><surname>Sherman</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><forename type="middle">W</forename><surname>Ladenson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Schlumberger</surname></persName>
		</author>
		<idno type="DOI">10.1210/jc.2008-1747</idno>
		<idno type="PMID">19158200</idno>
		<ptr type="open-access" target="https://academic.oup.com/jcem/article-pdf/94/4/1310/10806937/jcem1310.pdf" />
	</analytic>
	<monogr>
		<title level="j">The Journal of Clinical Endocrinology &amp; Metabolism</title>
		<title level="j" type="abbrev">The Journal of Clinical Endocrinology &amp; Metabolism</title>
		<idno type="ISSN">0021-972X</idno>
		<idno type="ISSNe">1945-7197</idno>
		<imprint>
			<biblScope unit="volume">94</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="1310" to="1316" />
			<date type="published" when="2009-04" />
			<publisher>The Endocrine Society</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Does Recombinant Human Thyrotropin-Stimulated Positron Emission Tomography with [18F]Fluoro-2-Deoxy-d-Glucose Improve Detection of Recurrence of Well-Differentiated Thyroid Carcinoma in Patients with Low Serum Thyroglobulin?</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Pierre</forename><surname>Vera</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Caroline</forename><surname>Kuhn-Lansoy</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Agathe</forename><surname>Edet-Sanson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Sebastien</forename><surname>Hapdey</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Romain</forename><surname>Modzelewski</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Anne</forename><surname>Hitzel</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Joelle</forename><surname>D'anjou</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jean-Pierre</forename><surname>Basuyau</surname></persName>
		</author>
		<idno type="DOI">10.1089/thy.2008.0416</idno>
		<idno type="PMID">20017617</idno>
		<ptr type="open-access" target="http://pdfs.semanticscholar.org/1f34/8849af2825d1417acac242bd899f6f1edb40.pdf" />
	</analytic>
	<monogr>
		<title level="j">Thyroid</title>
		<title level="j" type="abbrev">Thyroid</title>
		<idno type="ISSN">1050-7256</idno>
		<idno type="ISSNe">1557-9077</idno>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="15" to="23" />
			<date type="published" when="2010-01" />
			<publisher>Mary Ann Liebert Inc</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Influence of rhTSH on 18 FDG uptake in a population of 42 patients with suspected recurrence of differentiated thyroid carcinoma</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Hevrouet</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Devillers</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Cuggia</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">M</forename><surname>Bernard</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Le</forename><surname>Jeune</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Le</forename><surname>Dortz</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Herry</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">Y</forename><surname>Garin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Med Nucl</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="page" from="321" to="330" />
			<date type="published" when="2009" />
		</imprint>
	</monogr>
	<note>In French</note>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Poorly Differentiated Thyroid Carcinoma: The Turin Proposal for the Use of Uniform Diagnostic Criteria and an Algorithmic Diagnostic Approach</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Marco</forename><surname>Volante</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Paola</forename><surname>Collini</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yuri</forename><forename type="middle">E</forename><surname>Nikiforov</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Atsuhiko</forename><surname>Sakamoto</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Kennichi</forename><surname>Kakudo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ryohei</forename><surname>Katoh</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ricardo</forename><forename type="middle">V</forename><surname>Lloyd</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Virginia</forename><forename type="middle">A</forename><surname>Livolsi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Mauro</forename><surname>Papotti</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Manuel</forename><surname>Sobrinho-Simoes</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Gianni</forename><surname>Bussolati</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Juan</forename><surname>Rosai</surname></persName>
		</author>
		<idno type="DOI">10.1097/pas.0b013e3180309e6a</idno>
		<idno type="PMID">17667551</idno>
	</analytic>
	<monogr>
		<title level="j">The American Journal of Surgical Pathology</title>
		<title level="j" type="abbrev">The American Journal of Surgical Pathology</title>
		<idno type="ISSN">0147-5185</idno>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="1256" to="1264" />
			<date type="published" when="2007-08" />
			<publisher>Ovid Technologies (Wolters Kluwer Health)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">The value of FDG-PET in the follow-up of differentiated thyroid cancer: a review of the literature</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">P</forename><surname>Stokkel</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">S</forename><surname>Duchateau</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Dragoiescu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Q J Nucl Med Mol Imaging</title>
		<imprint>
			<biblScope unit="volume">50</biblScope>
			<biblScope unit="page" from="78" to="87" />
			<date type="published" when="2006" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Diagnostic value of positron emission tomography/computed tomography with fluorine-18 fluordeoxyglucose in patients with differentiated thyroid gland carcinoma, high thyroglobulin serum levels and negative iodine whole body scan</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><forename type="middle">Y</forename><surname>Yamaga</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">L</forename><surname>Cunha</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Wagner</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">F</forename><surname>Thom</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">M</forename><surname>Daniel</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">B</forename><surname>Funari</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arq Bras Endocrinol Metabol</title>
		<imprint>
			<biblScope unit="volume">51</biblScope>
			<biblScope unit="page" from="581" to="586" />
			<date type="published" when="2007" />
		</imprint>
	</monogr>
	<note>In Portuguese</note>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Histopathologic characterization of radioactive iodine‐refractory fluorodeoxyglucose‐positron emission tomography‐positive thyroid carcinoma</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Michael</forename><surname>Rivera</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ronald</forename><forename type="middle">A</forename><surname>Ghossein</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Heiko</forename><surname>Schoder</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Daniel</forename><surname>Gomez</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Steven</forename><forename type="middle">M</forename><surname>Larson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">Michael</forename><surname>Tuttle</surname></persName>
		</author>
		<idno type="DOI">10.1002/cncr.23515</idno>
		<idno type="PMID">18484584</idno>
	</analytic>
	<monogr>
		<title level="j">Cancer</title>
		<title level="j" type="abbrev">Cancer</title>
		<idno type="ISSN">0008-543X</idno>
		<idno type="ISSNe">1097-0142</idno>
		<imprint>
			<biblScope unit="volume">113</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="48" to="56" />
			<date type="published" when="2008-07-01" />
			<publisher>Wiley</publisher>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
